Table 1 Clinical and pathological characterization of IBC versus non-IBC patients

Age

Range

29-60

33-67

0.001^a*

Mean ± SD

40.9 ± 7.5

49.9 ± 9.1

t- test

Tumor size‡

Mean ± SD

6.5 ± 3.3

4.31 ± 2.30

1.000^b

< 2

1 (5.6%)

1 (3.7%)

≥ 2

17 (94.4%)

26 (96.3%)

Tumor grade

I- II

15 (65%)

21 (77.8%)

0.511^b

III

8(35%)

6 (22.2%)

Axillary Lymph Node Status†

Negative

0(0%)

7 (25.9%)

0.037^b*

< 4

3 (15%)

9 (33.4%)

4-7

6 (30%)

6 (22.2%)

≥ 8

11(55%)

5 (18.5%)

ER

Positive

6 (27.3%)

6 (22.2%)

Negative

17 (72.7%)

21 (77.8%)

0.747^b

PR

Positive

7 (31.8%)

8 (29.6%)

1.000^b

Negative

16 (68.2%)

19 (70.4%)

HER-2

Positive

4 (18.2%)

4 (14.8%)

1.000^b

Negative

19 (81.8%)

23 (85.2%)

Lymphovascular invasion

Positive

17 (73.9%)

3 (11.1%)

0.000^b*

Negative

6 (26.1%)

24 (88.9%)

Tumor emboli

Positive

23 (100%)

3 (11.1%)

0.000^b*

Negative

0

24 (88.9%)